<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433613</url>
  </required_header>
  <id_info>
    <org_study_id>GOLD AF</org_study_id>
    <nct_id>NCT02433613</nct_id>
  </id_info>
  <brief_title>Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)</brief_title>
  <official_title>Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Atrial Fibrillation Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IHF GmbH - Institut für Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Atrial Fibrillation Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, single-arm, non-interventional and open-label registry. The
      purpose of the registry is to document use of Phased Radio Frequency Ablation (hereafter
      &quot;Phased RFA&quot;) System in a real world patient population with atrial fibrillation and evaulate
      its performance.

      Gold AF will enroll a minimum of 1,000 patients who undergo Phased RFA in approximately 38
      sites in Western, Central Europe, Israel and South Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry will collect data prospectively on patients with paroxysmal, persistent and
      longstanding persistent atrial fibrillation (hereafter &quot;AF&quot;) undergoing Phased RFA treatment.
      Phased RFA will be applied according to the 'Intended Use' in CE mark release and product
      packaging.

      The treatment will be performed according to routine hospital practice and no additional
      tests are required specific to the registry. This registry will serve as a tool to collect
      clinical data in order to expand the knowledge base of safety, effectiveness and
      functionality of the Medtronic Phased RFA System in a real world patient population.

      The key measures collected for the patients will be inclusive of, but are not limited to,
      clinical data pertaining to AF and individual disease state(s) characterized by form of AF
      and underline diseases, Phased RFA procedure details including timing and catheters in use,
      procedure and system related adverse events, AF recurrence, re-ablations and left atrial
      flutter rate after the index Phased RFA procedure. Additionally, this study will provide
      further information in the evolving anticoagulation strategies (e.g. continuous versus
      bridging and vitamin K antagonist versus novel oral anticoagulants) in the setting of AF
      ablations. Patients will be followed minimum for 12 months and maximum for 14 months after
      the Phased RFA ablation procedure. The twelve month follow-up can be done by telephone if it
      is not standard of care in the hospital's practice. During the twelve month follow-up
      patients will be interviewed with a quality of life questionnaire and results will be
      compared to the quality of life questionaire completed before the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Estimate Phased RFA mid-term success rate</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Success rate will be estimated as time to first event: AF recurrence and/or left Atrial Flutter. Parameters of interest include: re-ablations, ECG/EGM recorded AF, electrical and pharmacological cardioversions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate Phased RFA mid-term safety</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Estimate major procedure/system related complications of Phased RFA</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute procedural success rate</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Procedure considered successful if all PVs were isolated (entrance and/or exit block confirmation per vein) and procedure was not declined due to technical issues related to Phased RFA system</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural efficiency</measure>
    <time_frame>Patient will be followed in the Catheterization Laboratory (hereafter &quot;CathLab&quot;)/operating room during approximately 2 hours of Phased RFA procedure duration</time_frame>
    <description>Parameters to measure the efficiency: procedure duration, laboratory occupancy duration, fluoroscopy time, Phased RFA consumables used, adjunctive devices (mapping or navigation systems) used</description>
  </other_outcome>
  <other_outcome>
    <measure>Peri-procedural anticoagulation therapy</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Characterize anticoagulation therapy: utilization of vitamin K antagonists (VKA), international normalized ratio (INR), novel oral anticoagulants (NOAC), activated clotting time (ACT) during the procedure, peri -procedural &quot;bridging&quot; vs &quot;no bridging&quot; strategy. Correlate anticoagulation therapy with thromboembolic events and bleeding the peri -procedural thromboembolic events and bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Single catheter PVAC GOLD utilization in persistent AF ablation</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased RFA</time_frame>
    <description>Evaluate which tools participating centers use (MAAC and/or MASC and/or PVAC GOLD) in persistent and long standing persistent AF and to verify patient's characteristics, procedure approaches and estimates outcome across participating sites. The main interest is if PVAC GOLD catheter can be utilized as a single catheter for patients with persistent AF and analyze AF recurrence rate in this group</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life dynamic</measure>
    <time_frame>Patient will be followed for minimum 12 months, maximum 14 months after index Phased</time_frame>
    <description>Quality of life will be captured using the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. It is a standardized, disease-specific, reliable and responsive measure of health-related quality of life in subjects with AF. The AFEQT is a self-reported questionnaire with responses on a 7-point Likert scale. The 20-item instrument is divided into three domains (4-item symptom score, 8-item daily activities score, 6-item treatment concerns score) plus two treatment satisfaction questions.In countries where no validated version is available yet (e.g. Israel, Portugal), the AFEQT questionnaire will not be applied or will be additionally validated for the country official languages according to local requirements and regulations</description>
  </other_outcome>
  <enrollment type="Actual">1071</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible are all patients with paroxysmal, persistent and long-standing persistent AF who
        fulfill all inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient with AF who is scheduled for Phased RFA procedure

          -  Patient signed patient informed consent or patient data release form

          -  Age ≥18 years old To avoid enrollment bias in this cohort of patient and reflect &quot;real
             world&quot; clinical practice for Phased RFA no exclusion criteria will be defined.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas Boersma, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonious</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meleze Hocini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cardiologique du Haut-Lévêque</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMC Parly 2</name>
      <address>
        <city>Le Chesney</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint-Denis</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jo Ann Medical Center</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum Oberallgäu-Kempten</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz-Krankenhaus Paderborn</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Alexandra</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Barzilai Medical Center Ashkleon</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osped. Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Osped. S.Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden B.V.</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 4</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 2</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Wojskowy Szpital Kliniczny</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Notre - Hospital de Santa Maria E.P.E.</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Donostia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna AG</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Vein Isolation</keyword>
  <keyword>Phased Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

